A research of L-Carnitine for general fatigue during chemothearpy in patients with advanced gastric cancer

A research of L-Carnitine for general fatigue during chemothearpy in patients with advanced gastric cancer - A research of L-Carnitine for general fatigue during chemothearpy in patients with advanced gastric cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012141

Enrollment

Registered

2013-12-01

Start date

2013-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

L-Carnitine group A 2000mg/day of L-Carnitine was administered on days 1 to 28. CDDP and TXT were intravenously administered on days 1 and 15, and S1 was orally administered day 1to 7 and 15 to 21. O

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients aged 20 years to 75 years 2.Patients with stage III gastric cancer 3.Patients receving neoadjuvant chemotherapy 4.Patients who can answer the queries 5.Patients who gaved informed consent

Exclusion criteria

Exclusion criteria: 1.Patients who has allergy for L-carnitine 2.Pregnant patients or patients who hope pregnancy 3.Patients who are judged inappropriate by doctors

Design outcomes

Primary

Measure	Time frame
BFI score	—

Secondary

Measure	Time frame
1)Nutritional assessment Alb, Hb, BMI, Amount of muscle 2)Tumor diameter 3)Adverse effect 4)Carnitine (total calnicin, free calnicin, acil calnicin)	—

Countries

Japan

Contacts

Public ContactChikara Kunisaki

Yokohama City University Medical Center Gastroenterological Center

s0714@med.yokohama-cu.ac.jp045-261-5656

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026